Randomized Control Trial of Total Arch Replacement with Frozen Elephant Trunk Versus Conventional Hemiarch Replacement in Patients with Acute Type a Aortic Dissection (TARFET-TAAD)

Acute Type A aortic dissection (ATAAD) and its complications are life-threatening conditions that cause more than 1400 hospital admissions and 300 deaths every year in Hong Kong and cause 172,927 deaths globally in 2019. There is an increasing trend in recent years.
Given the hyperacute presentation and complexity of the clinical manifestation with various mal-perfusion syndromes, the mortality of ATAAD remained high in all international reported registries and published series.
Conventional Hemiarch (HAR) replacement has been the gold standard procedure for ATAAD in most of cardiac surgical centers around the world because of the relative simplicity of the procedure. However, around 50-70% of patients were reported to develop distal anastomosis new entry after hemiarch procedure and for those with entry tear over aortic arch and distal mal-perfusion, hemiarch alone might not be able to solve the downstream problem. On the other hand, total arch replacement and frozen elephant trunk procedure (TARFET) is more complex, technically demanding procedure that could potentially cover/resect the arch entry tear and exclude tear over proximal descending thoracic aorta and, hence, solve the distal mal-perfusion syndrome. To date, there is no randomized control trial to answer whether HAR or TARFET procedure is superior in patients with ATAAD and entry tear is over the aortic arch or proximal descending thoracic aorta.
We plan to conduct a multi-center trial to recruit consecutive patients with ATAAD with entry tear beyond ascending aorta and randomized them, after informed consent, into either the conventional hemiarch replacement group (HAR) or total arch replacement and frozen elephant trunk (TARFET). The participating centers will collect pre- operative, intra-operative and post-operative clinical parameters for two groups of patients via REDCap system. Written informed consent, specifically allowing the use of clinical records for this randomized study, will be obtained from every patient prior to data collection. The primary outcome is the 30-day mortality of the ATAAD patients with surgically treated by HAR versus TARFET approach. The secondary outcomes are the major adverse cardiovascular and cerebral events, post-op renal replacement therapy, re-exploration for bleeding and re-intervention within 30-days.
This study will be the world's first multi-center randomized control trial in ATAAD to compare the 30-day mortality of patients treated with HAR and TARFET. It could be a guideline-changing study for the treatment of ATAAD and its impact on the surgical approach to patients suffering from ATAAD.

开始日期2026-10-01

申办/合作机构

香港中文大学

[+2]

NCT06865573

/ Not yet recruitingN/AIIT

Reintegration, Coping, and Care of Families After Inpatient Child and Adolescent Psychiatric Treatment

The goal of this longitudinal mixed-methods study is to investigate caregiver strain, family processes and health outcomes after youth psychiatric inpatient treatment. Caregivers of youth who received inpatient treatment for mental health problems will complete a survey at three timepoints (baseline, 3- and 6- month followup) reporting on youth outcomes, caregiver well-being, and family processes. Qualitative interviews on caregivers' challenges, needs, and resources around the return to home care are conducted with a subsample (target n = 10) of participants.
The main research questions (RQs) are:
RQ 1: Do family processes contribute to youth mental health outcomes after discharge from inpatient treatment? RQ 1a: What family-level risk factors predict youth readmission to inpatient treatment? RQ 1b: Do family processes predict youth mental health trajectories over time? RQ 2: Is there a reciprocal relationship between youth mental health problems and caregiver burden? RQ 2a: Do family processes mediate the association between caregiver burden and youth mental health problems? RQ 3: How do caregivers experience their children's return to home care? RQ 3a: What challenges and needs do caregivers report? RQ 3b: What types of follow-up services do families receive and/or have access to? RQ 3c: How do caregivers cope with ongoing difficulties in the post-discharge period?

开始日期2025-05-01

申办/合作机构

University of Vienna

NCT06527248

/ Not yet recruitingN/AIIT

Effects of Dietary Nitrate From Beetroot Juice on Vascular Function and Adaptations to Exercise Training in Postmenopausal Women: a Randomized, Placebo-controlled Study

The purpose of this clinical study in women after menopause is to investigate whether the daily intake of nitrate from beetroot juice over 12 weeks enhances the positive effect of exercise training on vascular function, blood pressure and physical performance.
The risk of cardiovascular diseases (CVD) increases with advancing age and women are particularly affected. In women, the decline in the sex hormone oestrogen in the blood circulation with menopause contributes to impaired vascular function and an increased CVD risk; in part through increased inflammatory processes, oxidative stress, and a reduced body's own production of nitric oxide (NO). NO is a signaling molecule that is important for vascular function. Endurance-based exercise training is a key lifestyle strategy to prevent CVD. However, studies indicate that exercise is less effective in terms of its health-promoting adaptations in women after menopause as compared with men of similar age.
This study investigates the effect of exercise training in combination with the intake of nitrate-rich beetroot juice on functions of the cardiovascular system. Nitrate is a nitrogen compound that is found naturally in plant foods (e.g. beetroot juice) and is converted to NO in the human body. Results of previous studies indicate vasodilatory, blood pressure-lowering and performance-enhancing effects as well as positive influences on inflammatory processes and oxidative stress following nitrate intake. The hypothesis is that nitrate intake concomitant to training promotes training adaptations and further improves vascular function, blood pressure and physical performance compared to training without nitrate intake.
For the study, 54 untrained postmenopausal women (with the ages between 45 and 65 years) will be recruited and randomly allocated into two groups. Both groups will undergo 12 weeks of endurance-based exercise training. One group will receive nitrate-rich beetroot juice, and the other nitrate-depleted beetroot juice (as placebo). Vascular function, blood pressure, maximum oxygen uptake, and blood biomarkers for nitrate metabolism, inflammation status and oxidative stress will be examined.
The anticipated study results will provide new insights into whether nitrate as a 'training adjunct' improves health-promoting training adaptations in women after menopause. The overall aim is to improve the cardiovascular health and performance of middle-aged women and reduce their increased CVD risk.

开始日期2025-01-01

申办/合作机构

University of Vienna

[+4]

100 项与 University of Vienna 相关的临床结果

登录后查看更多信息

0 项与 University of Vienna 相关的专利（医药）

登录后查看更多信息

106,006

项与 University of Vienna 相关的文献（医药）

2025-12-31·Systematics and Biodiversity

Phylogenetic divergence is associated with biogeographic divergence in sect. Hymenobrychis ( Onobrychis , Fabaceae): molecular phylogenetic and morphological evidence

作者: Nafisi, Haniyeh ; Kazempour-Osaloo, Shahrokh ; Kaveh, Akram ; Schneeweiss, Gerald M. ; Amirahmadi, Atefe

2025-12-31·Journal of Maps

Home is where my villa is: a machine learning-based predictive suitability map for Roman features in Northern Noricum (ca. 50–500 CE/Lower Austria/AUT)

作者: Hagmann, Dominik

2025-12-31·Health Psychology and Behavioral Medicine

Health behaviours and mobile intervention use in patients recruited from general practitioners’ practices in rural Bavaria

Article

作者: König, Laura M. ; Bartelmeß, Tina ; Al Masri, Mirna ; Betz, Constanze

Introduction: Individuals living in rural areas report poorer health outcomes, including obesity, compared to individuals living in urban areas. Amongst others, this is due to restricted access to opportunities for healthy eating and physical activity. Interventions are urgently needed to address this gap. It is yet unclear whether digital interventions are suited for this purpose. The present dataset provides information on adults residing in rural Germany regarding their health status, perceived access to opportunities for healthy eating and physical activity, and digital device ownership and intervention use. Materials and methods: A pen-and-paper survey was conducted in winter 2022/2023 among patients of five general practitioners' practices in rural Bavaria. Materials and data are openly available for future use. Data description: The dataset contains responses from N = 273 individuals (54.9% women, 44.8% men, 0.4% diverse; age M = 51.3, SD = 16.7; BMI M = 29.1, SD = 15.9). On average, 30.6 participants failed to respond to any given item (SD = 33.0; range 1-136). Eighty-four percent had access to the internet and a computer and 91.4% owned a smartphone, but the majority (58.5%/ 84.2%) had no prior experience with mobile physical activity or dietary interventions, respectively. Discussion: This dataset provides insights into barriers and facilitators to healthy eating and physical activity in rural populations and digital (health) technology use. It provides starting points for behavioural weight management interventions in rural areas.

项与 University of Vienna 相关的新闻（医药）

2025-04-29

·PRNewswire

Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion

LUND, Sweden, April 29, 2025 /PRNewswire/ -- First quarter Net sales amounted to SEK 12.3 million (9.4). Operating result amounted to SEK -18.0 million (-18.4). Earnings per share, before and after dilution, amounted to SEK -0.07 (-0.11). Cash flow from operating activities amounted to SEK -8.5 million (-7.3). Comments from CEO Claus Egstrand "Enzymatica's progress and future prospects are clearly reflected in the strong first quarter of 2025. ColdZyme continues to perform strongly in the pharmacy sector, growing faster than the overall market and resulting in additional market share gains. Sales increased by 31.5% in Sweden and 19.5% in the UK compared to the same period last year – clear proof that ColdZyme is both reaching consumers and being appreciated. However, sales in our home markets represent only a small part of our future vision, and our patented technology paves the way for significant sales growth – through new markets and partnerships," says Claus Egstrand, CEO. Significant events during the quarter On February 28, 2025, two independent studies on ColdZyme were published in the scientific journal The Journal of Physiology. The studies, conducted at the University of Kent and the University in Vienna, showed that ColdZyme both reduces viral load by 94% and alleviates cold symptoms. The clinical study, based on 154 participants, demonstrated fewer sick days and milder symptoms. The in vitro study confirmed that ColdZyme effectively prevents viruses from infecting cells in the upper respiratory tract. These results further strengthen the evidence for ColdZyme's therapeutic effect. Significant events after the quarter No significant events have been reported after the quarter. Other events during and after the quarter On March 5, 2025, Enzymatica held a press conference, both physically and digitally, where Professor Glen Davison and Professor Doris Wilflingseder presented their findings from the recently published article in The Journal of Physiology. The presentation was followed by a company update. Both recordings are available for viewing on the company's website.at The information in this press release is such that Enzymatica is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on April 29, 2025, at 08:30 CET. For more information, please contact: Claus Egstrand, CEO, Enzymatica AB Mobile: +44 7780 22 8385 | Email: [email protected] Enzymatica AB is headquartered in Lund and is listed on the Nasdaq First North Growth Market. For more information, visit . Enzymatica's Certified Adviser is Carnegie Investment Bank AB (publ). This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

财报临床结果

2025-04-08

·化学经纬

模块化合成双手性二级胺

手性胺类分子具有重要药学应用价值，但目前对具有多个手性中心复杂胺的合成还缺乏通用方法（图1A）。如何在实现结构多样性的同时连续精确构建多个碳手性中心是主要挑战。以双α-手性胺合成为例，单一碳手性构建有诸多方法实现，但该碳中心的立体化学会诱导第二个碳手性构建过程的非对映选择性（邻基效应，图1B），导致无法精准合成任意单一构型的目标分子。针对上述问题，高兵团队从廉价易得的Ellman试剂出发，通过连续手性诱导/转移策略，成功实现双α-手性胺以及更复杂分子的模块化合成（图1C）。图1. 手性胺的研究背景以及该工作的合成策略。该策略成功的关键步骤是亚磺酰胺与炔酰胺在酸性条件下进行的重排反应，由该课题组和维也纳大学的Maulide教授各自独立开发。不过前期的重排体系并没有探究多手性底物的影响。为探究邻基效应对重排反应的影响，作者进行了相关控制实验。结果表明，重排反应体系中并没有显著的邻基效应，且无论是调换硫手性中心还是碳手性中心，反应最终都能以优异的非对映选择性（>99:1）给出相应的产物（图2A）。随后作者验证了该结论在不同结构的叔丁基亚磺酰胺和炔酰胺中的适用情况（图2B）。实验数据表明，C-2手性中心的立体化学完全由叔丁基亚磺酰胺结构中硫手性单元控制，并不会受到其它因素的干扰（图2B）。作者通过计算化学揭示了其内在原因：在重排反应五元环状过渡态中（TS-E-R1，图2A和2C），C-1单元因远离C-2中心而无法对其造成影响（图2C）。图2. 手性亚磺酰胺促进的[2, 3]-重排反应的立体化学和适用范围通过亲核试剂对亚胺的加成、亚胺的还原以及亚胺参与的过渡金属催化偶联等多样化合成方法，作者制备了种类丰富的N-烷基手性叔丁基亚磺酰胺，并对其进行了系统性测试（图3）。结果显示，重排反应体系兼容各种官能团修饰的叔丁基亚磺酰胺（产物非对映异构体比例均大于20:1），包括炔基（17），吲哚基（18），α, β-不饱和酯（19），芳香酮（20），二氟烷基（21），磷酰基（22），硅基（24，31），烯丙基（25，26），硅氧基（28），甚至是酰胺基（29）。为了确认产物的绝对构型作者对产物25a和25b进行了X-射线衍射分析，最终确认其构型分别为（RC-1, RC-1）和（SC-1,SC-1）。此外，针对结构更为复杂的稠环化合物，作者同样进行了合成与测试，结果均能以优异的非对映选择性给出相应的产物（23，27）。图3. 通过连续的手性诱导和转移策略实现双α-手性胺的立体选择性合成此后，利用CTS（Closed Transition State）和OTS（Open Transition State）两种不同机制主导下的手性诱导策略，作者分别制备了S32和S33的所有异构体并对其进行了测试（图4）。结果表明，叔丁基亚磺酰胺介导的手性诱导和手性转移事件的组合可以实现双α-手性胺全部立体异构体的模块化合成。图4. 双α-手性胺所有立体异构体的模块化合成为展示该方法的实用性，作者进一步对手性诱导和手性转移两步反应进行简化。以合成分子22b为例，前一步的粗产品S22可不经柱层析直接投入重排反应体系，最终以65%的收率和优秀的非对映选择性获得了目标产物（图5A）。作者还展示了产物后期转化的巨大潜力，包括酰胺的还原（34）、酯化（35）、胺化（36）以及氰基的水解（37）。这些转化为结构更为丰富的手性二级胺的快速合成提供了可能（图5B）。此外，作者也尝试了结构更为复杂的手性三级胺和手性N, P-配体的合成，最终均能以优异的立体选择性获得目标化合物（图5B）。最后，作者利用该策略成功实现了Benazepril、Enalapril等药物分子骨架的立体可控式合成。图5. 反应的实用性和应用价值展示综上，湖南大学高兵团队以叔丁基亚磺酰胺为核心底物，成功开发了一种模块化合成双α-手性胺的通用方法。该方法不仅原料易得，操作简单，而且具有立体可控和可预测等优点，为快速构建复杂手性胺，进而加速药物开发的新进程提供强有力的支撑。参考文献:Sci. Adv., 2025, DOI: 10.1126/sciadv.adv2010

诊断试剂临床研究临床结果

2025-02-10

·派真生物PackGene

一周要闻丨基因治疗要闻速递第137期

行业动态速览热点聚焦 01 罕见病组织获569万美元资助，推进脊髓小脑共济失调3型基因治疗 2025 年 2 月 6 日，康涅狄格州伍德布里奇——罕见病治疗组织 Cure Rare Disease (CRD) 宣布获得加州再生医学研究所 (CIRM) 569 万美元的资助，用于推进针对脊髓小脑共济失调 3 型 (SCA3) 的反义寡核苷酸疗法的开发。SCA3 是一种目前尚无治疗方法的神经退行性疾病。推荐阅读：罕见病组织获569万美元资助，推进脊髓小脑共济失调3型基因治疗 02 微光基因成功完成Pre-A轮融资，助力常见病表观遗传编辑研究！微光基因(苏州)有限公司（以下简称“微光基因”）宣布成功完成Pre-A轮融资，融资总额达到数千万元人民币。本轮融资由广州产投集团和广州优玖投资共同投资；浩悦资本担任本轮融资财务顾问并将担任后续融资独家财务顾问。此次融资助力微光基因快速推进针对未满足临床需求的常见病表观遗传编辑管线研究。推荐阅读：微光基因成功完成Pre-A轮融资，助力常见病表观遗传编辑研究！ 03 北大Nature：新一代线粒体碱基编辑器来了 2025年1月22日，昌平实验室及北京大学魏文胜课题组在Nature杂志在线发表了题为“Precise modelling of mitochondrial diseases using optimized mitoBEs”的研究论文。该研究报道了通过优化后的mitoBEs实现高效且精准地构建线粒体疾病小鼠模型的成果。利用优化版mitoBEs，研究团队成功建立了具有高突变频率的小鼠模型，这些模型表现出了与疾病相关的典型表型。此外，通过杂交实验，还获得了突变负荷达到100%以及仅含单碱基突变的精确小鼠模型。推荐阅读：北大Nature：新一代线粒体碱基编辑器来了 04 Viralgen和Axovia合作开发针对视网膜营养不良的基因疗法近日， Viralgen和Axovia Therapeutics确认合作伙伴关系，以推进一种基于AAV9的基因疗法的开发和生产，该疗法用于治疗因BBS1基因突变导致视网膜营养不良的Bardet-Biedl综合征（BBS）患者，此次合作旨在预防BBS患者的视力丧失。推荐阅读：行业资讯 | Viralgen和Axovia合作开发针对视网膜营养不良的基因疗法 05 信念医药DMD AAV基因疗法IND获受理，此前已获FDA批准 2025年2月5日，信念医药集团（下称“信念医药”）宣布，其杜氏肌营养不良（DMD）基因治疗药物BBM-D101注射液的临床试验申请（IND）已获国家药品监督管理局（NMPA）受理。推荐阅读：信念医药DMD AAV基因疗法IND获受理，此前已获FDA批准 06 《自然》发布2025年值得关注的七项技术，生命科学领域占四席，涉及细胞基因疗法、AI生物学基础模型等近期，《自然》杂志发布了“2025年值得关注的七项突破性技术”。这七项值得关注的突破性技术包括：通过CAR-T细胞基因疗法治疗实体瘤与自免疾病、利用微生物降解塑料及其他污染物、AI生物学基础模型帮助理解复杂的生物系统、微生物单细胞分析技术、AI自动化实验室助力材料科学研究、利用新型材料减少城市热岛效应、光子计算技术。其中生命科学领域占四席。推荐阅读：《自然》发布2025年值得关注的七项技术，生命科学领域占四席，涉及细胞基因疗法、AI生物学基础模型等创新突破 01 广州健康院开发新型单细胞谱系追踪技术，揭秘细胞命运之谜 2025年1月28日，中国科学院广州生物医药与健康研究院彭广敦研究团队在《细胞·报告》（Cell Reports）发表重要研究成果，成功开发出名为“DuTracer”的新型单细胞谱系示踪技术。该技术通过巧妙结合两种基因编辑工具CRISPR-Cas9和Cas12a，显著提升了细胞谱系追踪的精度和深度，为解析胚胎发育、器官再生及疾病机制提供了全新工具。推荐阅读：广州健康院开发新型单细胞谱系追踪技术，揭秘细胞命运之谜 02 炎症基因表达调控的新机制——TTP与pre-mRNA的“命运决定” 2025年1月24日，来自维也纳大学的Pavel Kovarik团队在Molecular Cell杂志上发表题为 Cytoplasmic mRNA decay controlling inflammatory gene expression is determined by pre-mRNA fate decision 的研究论文。研究表明，TTP通过形成一种先后层级分明的分子组装体来破坏目标mRNA的稳定性。这种组装体的形成严格依赖于TTP与RNA在细胞核中的互作。而细胞质中mRNA降解复合体的组装是在细胞核内就被TTP与pre-mRNA的互作所决定。研究人员发现pre-mRNA而非成熟mRNA是TTP的主要靶标。因此，炎症诱导的mRNA的命运在其合成之时便已决定。这一机制确保了无论转录水平如何，都能防止过量且可能有害的炎症因子被翻译出来。推荐阅读：Mol Cell | 炎症基因表达调控的新机制——TTP与pre-mRNA的“命运决定” 03 听力障碍基因治疗新思路！《Science》发表我国科学家破解耳蜗听觉毛细胞发育“基因密码” 最近，《Science》期刊在线发表了题为《Casz1 is required for both inner hair cell fate stabilization and outer hair cell survival》的研究论文，该研究由中国科学院脑科学与智能技术卓越创新中心（神经科学研究所）刘志勇研究组完成。该项研究报道了锌指转录因子Casz1在听觉毛细胞（hair cell, HC）命运稳定与生存维持中的双重作用，并解析了Casz1发挥功能的分子机制，为探索基因操纵修复听觉损伤提供了新的思路和靶点。推荐阅读：听力障碍基因治疗新思路！《Science》发表我国科学家破解耳蜗听觉毛细胞发育“基因密码” 资本政策 01 加强细胞与基因治疗、“AI+医药”、再生医学等特色赛道等基础研究与核心技术攻关，天津市发布全链条支持生物医药创新发展若干措施的通知推荐阅读：加强细胞与基因治疗、“AI+医药”、再生医学等特色赛道基础研究与核心技术攻关，天津市发布全链条支持生物医药创新发展若干措施的通知 02 注资5000亿美元，美国启动“星际之门计划”，利用AI+mRNA技术加速癌症治疗进程近日，在白宫新闻发布会上，美国总统特朗普宣布启动“星际之门计划”，由软银、OpenAI、甲骨文等顶尖巨头联合推动，注资5000亿美元。计划通过AI设计mRNA药物，重塑癌症治疗。OpenAI CEO山姆·奥特曼表示：“这将是这个时代最重要的项目。” 推荐阅读：注资5000亿美元，美国启动“星际之门计划”，利用AI+mRNA技术加速癌症治疗进程参考资料： 1.https://mp.weixin.qq.com/s/Z-21VQrhw64rNsqolSxl_Q 2.https://mp.weixin.qq.com/s/pMWYcBr_ce6pv-qQDU3x-A 3.https://mp.weixin.qq.com/s/Ek6Y7u-mWtw7UPKqQPdBEw 4.https://mp.weixin.qq.com/s/HI3DTJSwOve4N8eGeCwbGA 5.https://mp.weixin.qq.com/s/iWL3JAvjtnkyDcUcbEHR6g 6.https://mp.weixin.qq.com/s/NKU7-u6PNZSQByZW6ATqug 7.https://mp.weixin.qq.com/s/uyvf4m6QHQ72Mbqh2xCOvA 8.https://mp.weixin.qq.com/s/h-asfTpVDonZ2GwcEvnH3Q 9.https://mp.weixin.qq.com/s/gvMVDZbK5PRss5NRp_a8dQ 10.https://mp.weixin.qq.com/s/34eQYdL-b1WT1D0Fy0eMcw 11.https://mp.weixin.qq.com/s/F360cjDHDssj2_405_aUqw 关于派真生物

基因疗法临床申请细胞疗法寡核苷酸临床研究

100 项与 University of Vienna 相关的药物交易

登录后查看更多信息

100 项与 University of Vienna 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年06月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

PDL1 modulators(University of Vienna) ( PDL1 )	-	临床前
STS-66 ( NKCC1 )	脑损伤更多	临床前
KP-692 ( ATP2A1 x DNA x SERCA2 )	肿瘤更多	无进展
DAT antagonists(University of Vienna) ( DAT )	-	无进展
FFC-24	实体瘤更多	无进展